红色素形成刺激剂对肺癌患者的影响:元分析
Zhenhua Tong1, Zhumeng Xu2, Yaqi Duan3
1Department of Research and Training, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenyang, 110016, China.
Clinical and experimental medicine
|July 5, 2024
概括
红色素形成刺激剂 (ESAs) 可能会降低肺癌患者的死亡率和输血,但会增加血栓事件. 需要进一步的研究来澄清ESA在这个人群中的风险和好处.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 红色素形成刺激剂 (ESAs) 用于治疗癌症患者的贫血,可能改善生活质量.
- 然而,人们对ESA可能增加死亡率和血栓性血管事件存在担忧.
- 欧洲电子元件对肺癌患者的特定影响,包括不同的组织学亚型,需要详细调查.
研究的目的:
- 进行随机对照试验 (RCT) 的元分析,评估ESA在贫血肺癌患者的疗效和安全性.
- 评估ESA对死亡率,血栓性血管事件,输血需求和不良事件的影响.
- 根据肺癌亚型 (SCLC与NSCLC) 和特定的ESA剂,探索潜在的结果差异.
主要方法:
- 对2000年至2023年间发表的RCT进行了PubMed,Embase,Web of Science和Cochrane图书馆的系统搜索.
- 包括的研究是那些研究ESA用于肺癌患者贫血治疗的研究.
- 关于死亡率,血栓性血管事件,输血需求和不良事件的数据被提取并进行了元分析.
主要成果:
- 对8项RCT (4240名患者) 的分析表明,在排除一项研究后,ESA并没有显著增加肺癌患者的死亡率 (RR 0.99,95% CI 0.92-1.06),甚至可能减少 (RR 0.96,95% CI 0.92-0.99).
- 在Darbepoetin alfa和Epoetin alfa亚组中,ESA显著降低了对输血的需求 (RR0.56,95% CI 0.44-0.72).
- 与ESA一起观察到血栓性血管事件的显著增加 (RR 1.40,95% CI 1.13-1.72),而整体不良事件发生率没有显著差异.
结论:
- 在肺癌患者的死亡率方面,ESA似乎是安全的,并且有效地减少了输血需求.
- 然而,必须仔细考虑与ESA使用相关的血栓性血管事件的风险增加.
- 进一步的小组分析表明,在不同ESA和肺癌类型中减少输血需求具有一致的好处,尽管死亡率的好处需要仔细解释.
更多相关视频
相关概念视频
Factors Affecting Erythropoiesis
3.2K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.2K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Erythropoiesis
4.2K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
195
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195


